Chalcone-indole hybrid scaffolds as promising anticancer drug candidates: a mini-review
Future Medicinal Chemistry · 2026
DOI: 10.1080/17568919.2026.2714032 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, 2026. Verfasst von Yafei Zhuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Indoles, Chalcone, Neoplasms. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Doctoral research project of Hubei University of Science and Technology.
Abstract (Originalsprache)
Cancer treatment is hampered by severe systemic side effects, poor tumor selectivity, and multidrug resistance (MDR). Molecular hybridization integrates chalcone and indole, two privileged antitumor pharmacophores, into one scaffold to generate chalcone-indole hybrids that synergistically enhance antitumor potency, improve tumor targeting, and reverse MDR. This mini-review analyzes literature from 2020 to 2026 on chalcone-indole anticancer hybrids. Based on structural modification patterns, the reported hybrids are categorized into four subgroups: simple substituted, α/β-position modified, N-1 fatty acid-substituted, and multi-pharmacophore fused hybrids. For each category, we summarize structure-activity relationships (SARs), antiproliferative activity, selective toxicity, molecular mechanisms, and in vivo xenograft performance. Most lead compounds exert tumor-suppressive effects via tubulin polymerization inhibition, G2/M cell cycle arrest, ROS overaccumulation, and mitochondrial-dependent apoptosis. Representative hybrids 10a, 12a, 21a, and 25a exhibit remarkable efficacy against drug-resistant colorectal, lung, and breast tumors with favorable in vivo safety. We highlight the application potential of different subtypes for specific malignancies, including α/β-modified analogues for resistant colorectal cancer, N-1 fatty acid-platinum conjugates for platinum-resistant lung cancer, NLRP3 inhibitor 7a for oral cancer, and multi-pharmacophore fused derivatives for broad-spectrum activity. Current bottlenecks limiting clinical transformation are discussed. This review provides structural design rules for developing novel chalcone-indole targeted anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China.
- School of Public Health and Nursing, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Förderung
- the Doctoral research project of Hubei University of Science and Technology
Zitieren
APA
Zhuang, Y., Cheng, Y., Zhao, D., Yu, J., & Chen, L. (2026). Chalcone-indole hybrid scaffolds as promising anticancer drug candidates: a mini-review. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2026.2714032
Vancouver
Zhuang Y, Cheng Y, Zhao D, Yu J, Chen L. Chalcone-indole hybrid scaffolds as promising anticancer drug candidates: a mini-review. Future Medicinal Chemistry. 2026. doi:10.1080/17568919.2026.2714032
BibTeX
@article{Zhuang2026,
author = {Zhuang, Yafei and Cheng, Yanjing and Zhao, Danchen and Yu, Jun and Chen, Lianlian},
title = {Chalcone-indole hybrid scaffolds as promising anticancer drug candidates: a mini-review},
journal = {Future Medicinal Chemistry},
year = {2026},
doi = {10.1080/17568919.2026.2714032}
}
EUVIMED